Efficacy and toxicity of pemetrexed or vinorelbine plus cisplatin in treatment of patients with adenocarcinoma of lung

Objective: To observe the efficacy and toxicity of pemetrexed or vinorelbine plus cisplatin in treatment of patientswith adenocarcinoma of lung. Methods: The 53 cases of advanced adenocarcinoma lung were divided into vinorelbine plus cisplatin group (NC=27) and pemetrexed plus cisplatin group(PC group) in 29 cases. NC group:vinorelbine 25 mg/m²,days 1,8; cisplatin 25 mg/m²,2 to 4 days. PC group:pemetrexed 500 mg/m²,d day 1; cisplatin 25 mg/m²,2 to 4 days,every 3 weeks for a period of repeated,two cycles were evaluated. Results: Altogether 53 patients were evaluated. The effective rate in NC group was 41.67% and in PC group was 51.72%. The effective rate between the two groups was no significant difference(P > 0.05). The main toxicity vasculitis in NC group was 37.50% lower than the PC group 6.90% (P < 0.05). Other toxicity were hematological toxicity and gastrointestinal reactions, including nausea,vomiting,and can be tolerated. Conclusions: Pemetrexed plus cisplatin had the effective activity as vinorelbine plus cisplatin in treatment of patients with adenocarcinoma of lung, and they appeared to be more-tolerated. It can be a choice of drug therapy for adenocarcinoma of lung.